Full-Time

Associate Director

Market Access

Confirmed live in the last 24 hours

Arcellx

Arcellx

51-200 employees

Develops immunotherapies for cell therapy

Compensation Overview

$195k - $220k/yr

+ Bonus + Equity Grant

Senior

San Carlos, CA, USA

Relocation assistance is offered if required.

Category
Business Research
Business Development
Business & Strategy
Required Skills
Data Analysis
Requirements
  • Bachelor’s degree in life sciences, pharmacy, or business; advanced degree (MBA, MPH, PhD, or PharmD) preferred.
  • 6+ years of experience in market access, pricing, health economics, or related fields within the pharmaceutical or biotechnology industry, plus oncology/hematology experience.
  • Understanding of healthcare payer landscape and health systems environment.
  • Knowledge of promotional regulatory review processes.
  • Ability to take initiative, build productive relationships, work cross-functionally, and manage multiple projects.
Responsibilities
  • Support the development and execution of market access strategies for anito-cel.
  • Develop a compelling, differentiated value proposition for anito-cel through collaboration with marketing, medical, health economics and outcomes research (HEOR), real world evidence (RWE) and other relevant cross-functional partners.
  • Lead the creation, review, and approval of pre- and post-approval materials to support payer and health system stakeholder engagement.
  • Collaborate with HEOR/RWE teams to ensure that evidence relevant to access stakeholders is generated and communicated effectively.
  • Coordinate insights generation and analytics activities to inform access strategy and tactical plan.
  • Develop and deliver comprehensive training, tools, and resources to equip field teams.
  • Lead Field Input Team (FIT) team meetings to ensure access strategy and tactical plan are grounded in customer insights.
  • Provide strategic input into pricing, contracting, and distribution decisions.
Desired Qualifications
  • Advanced degree (MBA, MPH, PhD, or PharmD) preferred.

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products work by harnessing the body's immune system to target and eliminate diseased cells. Unlike many competitors, Arcellx focuses specifically on proprietary immunotherapy techniques that are still in the clinical stage, allowing them to tailor their treatments to address specific medical needs. The company's goal is to create safe and effective therapies that meet the needs of patients and healthcare providers, ultimately transforming the landscape of cell therapy.

Company Size

51-200

Company Stage

IPO

Headquarters

Gaithersburg, Maryland

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Kite enhances Arcellx's multiple myeloma program development.
  • Recent clinical data shows robust long-term responses for CART-ddBCMA.
  • Advancements in gene editing could improve Arcellx's CAR-T product efficacy.

What critics are saying

  • Competition from Legend Biotech and Johnson & Johnson's Carvykti is significant.
  • High costs of CAR-T therapies may limit market adoption and accessibility.
  • Dependence on partnerships like Kite could pose strategic risks.

What makes Arcellx unique

  • Arcellx's CART-ddBCMA has Fast Track and Orphan Drug designations from the FDA.
  • The ARC-SparX platform offers dosable and controllable CAR-T therapy options.
  • Anito-cel uses a novel D-Domain BCMA binder for enhanced multiple myeloma cell targeting.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Work Hours

401(k) Company Match

Fully-Paid Parental Leave

Tuition Reimbursement

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

5%

2 year growth

0%
Business Wire
May 21st, 2025
Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

Arcellx announces its participation at TD Cowen's 6th Annual Oncology Innovation Summit and its investor event During EHA2025.

Business Wire
Mar 20th, 2025
Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

Arcellx appoints Andrew Galligan and Kristin Myers to its Board of Directors.

BioSpace
Feb 28th, 2025
Arcellx To Participate At The Td Cowen 45Th Annual Health Care Conference

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, at 1:10 p.m. ET.A live webcast of this discussion will be accessible from Arcellx’s website at www.arcellx.com in the Investors section. A replay of the webcast will be archived and available for 30 days following the event.About Arcellx, Inc.Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible

Business Wire
May 9th, 2024
Kite And Arcellx Continue Momentum With Advances In Anito-Cel Multiple Myeloma Program

REDWOOD CITY, Calif. SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year. The trial will compare the efficacy and safety of anito-cel randomized against the standard of care (SOC) in patients with relapsed and/or refractory multiple myeloma (rrMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody

Business Wire
May 9th, 2024
Arcellx And Kite Continue Momentum With Advances In Anito-Cel Multiple Myeloma Program

REDWOOD CITY, Calif. SANTA MONICA, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year. The trial will compare the efficacy and safety of anito-cel randomized against the standard of care (SOC) in patients with relapsed and/or refractory multiple myeloma (rrMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody